Accel Diagnostics - Model RapidQ S-IgG Card - Rapid Semi-quantitative COVID-19 Serology Assay
A Rapid Test for the Quantitation of the Titer of Antibody Against the Spike Protein of the SARS-COV-2 VIRUS. Accel Diagnostics’ rapid quantitative COVID-19 serology assay for the detection and qualification anti-Spike SARS-COV-2 antibody concentration (IgG) is now available.
As in other viral infections, the immune system responds to COVID-19 by developing antibodies against the SARS-CoV-2 virus. The antibody titer (concentration) can reveal present and past infections and immunocompetence, as these antibodies vary differently with time from the onset of symptoms. Titer tests have been a valuable tool to determine individual immunity for other viral infections, such as rubella, measles, Hepatitis B, and Varicella.
Currently marketed lateral flow serological tests are qualitative assays and provide only a yes/no answer, hence they are unable to provide a full picture of the antibody titer, its trend over time, the course of infection, and possible level of immunity.
On the contrary, the RapidQ S-IgG Card combines ease of use, a low cost, and mobile connectivity with reliable quantitative antibody titer capabilities to aid in the identification of the disease progression, the degree of immunocompetence, and the spread of herd immunity.
can be made available to CLIA High Complexity Laboratory. This test is a Laboratory Developed Test (LDT) and it has not been cleared or approved by the U.S. Food and Drug Administration. The statements in the page have not been reviewed by the FDA.